cGMP compliant production cell line for SARS-CoV-2 (COVID-19) Spike S1 Protein (RBD)

To support COVID-19 research and accelerate the rapid clinical development of your product candidate, trenzyme has developed a cGMP compliant production cell line for the SARS-CoV-2 Spike S1 (RBD) protein based on the industry leading  CHOvolution® CHO-K1 platform (Celonic AG).
After completion of the development process of the production cell line, the high quality research cell bank (RCB) can be transferred to a CDMO (Contract Development and Manufacturing Organization) of your choice for further process development, optimization and high level production.

Our cGMP- compliant Production Cell Line package includes

Several high titer clones available

Full process documentation and certificates

Research Cell Bank (RCB), tested

more than 1 g/L at 1 L scale fed-batch based on CHOvolution® CHO-K1 cell line

Optimized production process, shake flask level (USP)

Optimized downstream purification process (DSP)

Easy transfer to your CDMO partner of choice

Non-GMP grade material in lower gram amounts available

Commercially available media

Analytical methods including potency assay (hACE2 binding)

Immunogenicity proven

High Quality - Made in Germany

Overview

Cell Line / Target Name CHO-K1 / SARS-CoV-2 Spike S1 Protein (RBD)
Catalog No. C2020-001-127

Target Synonyms

coronavirus spike protein; SARS-CoV-2 spike RBD; SARS-CoV-2
spike protein

Product Information

Parental Cell Line CHO-K1 (23-CHO-S)
Platform used CHOvolution™ (Celonic AG)
Product Titer > 1 g/L (determined by ELISA, shake flask process)

Additional Information

The domain of the SARS-CoV-2 Spike S1 (RBD) protein is the most important part of the viral spike protein and responsible for binding of the virus to the human receptor, the ACE-2 protein. Most patients recovered from COVID-19 have developed neutralizing antibodies against this protein, which has been proven by several animal studies. Therefore, it is the preferred target for vaccine development and neutralizing antibody production.

SDS-PAGE/Coll. Coomassie

Histogram of marked lanes in gel picture

SDS-PAGE of cGMP-compliant Cell Line for SARS-CoV-2 Spike-S1 (RBD) Histogram (of marked lane in gel picture) of cGMP-compliant Cell Line for SARS-CoV-2 Spike-S1 (RBD)

Fed-batch of final clones

Fed-batch screen of final clones of the cGMP compliant cell line for SARS-CoV-2 Spike S1 (RBD)  

Purified Protein (SARS-CoV-2 Spike S1 Protein (RBD)) is available.

Reinhold Horlacher, PhD

Reinhold Horlacher, PhD

Managing Director & CSO

We would be happy to provide you with your desired cell line and to support you on your cell line research project. If you have any questions or requests, our scientific experts will be happy to answer them shortly.

Get In Contact With Our Scientific Experts








    By submitting this form, I consent to trenzyme GmbH receiving and processing my data in order to process my inquiry. My consent is voluntary and I may revoke this consent at any time without providing any reasons, e.g. by sending an email to privacy(at)trenzyme.com with effect for the future. Further notices on data processing can be found in our privacy policy.